Ipsen’s Dysport® vs. Botox®: A Completed Study on Upper Limb Spasticity

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

Study Overview: Ipsen recently completed a study titled A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity. The study aimed to demonstrate the non-inferiority of Dysport® compared to Botox® in terms of safety and to establish Dysport®’s superiority in the duration of response in treating upper limb spasticity.

Intervention/Treatment: The study tested two biological interventions: AbobotulinumtoxinA (Dysport®) and OnabotulinumtoxinA (Botox®). These treatments are designed to manage upper limb spasticity by targeting overactive muscles.

Study Design: This Phase 4 study was interventional, using a randomized, crossover model. Participants received both treatments in a double-blind manner, ensuring neither the participants nor the care providers knew which treatment was administered at any time. The primary purpose was treatment-focused.

Study Timeline: The study began on June 9, 2021, and was completed by November 18, 2025. These dates are crucial as they mark the progression from initiation to the final update, indicating the study’s completion and readiness for result dissemination.

Market Implications: The completion of this study could significantly impact Ipsen’s market position, particularly if Dysport® is shown to be superior in duration of response. This could enhance investor confidence and potentially affect stock performance positively. Competitors in the botulinum toxin market, such as Allergan with Botox®, may need to reassess their market strategies in response to these findings.

The study is now completed, with further details available on the ClinicalTrials portal.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.